MedTrace Logo

High-Dose Chemotherapy in Treating Patients Undergoing Stem Cell Transplant for Recurrent or Refractory Hodgkin's Lymphoma

NCT00544570 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2010-02-09

No results posted yet for this study

Summary

RATIONALE: Giving high-dose chemotherapy before a peripheral blood stem cell transplant stops the growth of cancer cells by stopping them from dividing or by killing them. Giving colony-stimulating factors, such as G-CSF, helps stem cells move from the bone marrow to the blood so they can be collected and stored. The stem cells are then returned to the patient to replace the blood-forming cells that were destroyed by high-dose chemotherapy and radiation therapy.

PURPOSE: This clinical trial is studying the side effects and how well high-dose chemotherapy works in treating patients undergoing stem cell transplant for recurrent or refractory Hodgkin's lymphoma.

Conditions

Interventions

BIOLOGICAL

filgrastim

DRUG

carmustine

DRUG

cyclophosphamide

DRUG

etoposide

DRUG

melphalan

PROCEDURE

autologous hematopoietic stem cell transplantation

PROCEDURE

peripheral blood stem cell transplantation

RADIATION

radiation therapy

RADIATION

total-body irradiation

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • City of Hope Medical Center

    lead OTHER

Principal Investigators

  • Eileen P. Smith, MD · City of Hope Comprehensive Cancer Center

Study Design

Purpose
TREATMENT

Eligibility

Max Age
64 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1998-04-30
Primary Completion
2007-12-31
Completion
2007-12-31

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00544570 on ClinicalTrials.gov